29.05.20: Not intended for U.S. and UK Media - American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program):
Efficacy of Vitrakvi™ (larotrectinib) further established with continued high response rates and durable response in updated analyses in adult patients and quality of life data in adult and pediatric patients with TRK fusion cancer71% overall response rate (ORR) per investigator assessment and median duration of response of 35.2 months shown in expanded data set of 116 adult patients with TRK fusion cancer / Among patients with brain metastases, ORR was also 71% / Majority of adverse events (AEs) were grade 1 or 2, no new unexpected grade 3 or 4 AEs were reported / New analysis demonstrates clinically meaningful and ...
Source: Bayer IR Newsfeed: Events - May 29, 2020 Category: Pharmaceuticals Source Type: news
22.05.20: Not intended for U.S. and UK Media
Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 22, 2020 Category: Pharmaceuticals Source Type: news
19.05.20: Nine internationally recognized experts join Sustainability Council
Independent external council to advise Bayer's Board of Management on consistent implementation of its sustainability targetsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 19, 2020 Category: Pharmaceuticals Source Type: news
13.05.20: Not intended for U.S. and UK Media - New ARAMIS Phase III data to be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Nubeqa™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancerDarolutamide significantly reduced risk of death by 31 percent (HR=0.69, 95% CI 0.53-0.88; p=0.003) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Darolutamide significantly delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE) / Darolutamide continues to demonstrate a favorable safety profile, with no new safety signals observed, even with a longer treatment duration, ...
Source: Bayer IR Newsfeed: Events - May 14, 2020 Category: Pharmaceuticals Source Type: news
11.05.20: Not intended for U.S. and UK Media
Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific ProgramData on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Updated efficacy and safety data for larotrectinib (Vitrakvi®) from an expanded set of adult patients with TRK fusion cancer and a quality of life (QoL) analysis in adult and pediatric patients / New safety and efficacy data from established compounds including radium-223 dichloride (Xofigo®) and regorafenib (Stivarga®)mehr ... (Sour...
Source: Bayer IR Newsfeed: Events - May 12, 2020 Category: Pharmaceuticals Source Type: news
06.05.20: Post Q1 Virtual Roadshow
Post Q1 Virtual RoadshowLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 5, 2020 Category: Pharmaceuticals Source Type: news
05.05.20: Post Q1 Virtual Roadshow
Post Q1 Virtual RoadshowLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 4, 2020 Category: Pharmaceuticals Source Type: news
14.05.20: BMO Global Farm to Market Virtual Conference, New York, U.S.A.
BMO Global Farm to Market Virtual Conference, New York, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 30, 2020 Category: Pharmaceuticals Source Type: news
18.05.20: Berenberg Virtual USA Conference 2020, Tarrytown, U.S.A.
Berenberg Virtual USA Conference 2020, Tarrytown, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 30, 2020 Category: Pharmaceuticals Source Type: news
19.05.20: Bernstein Agricultural Webinar, London, UK
Bernstein Agricultural Webinar, London, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 30, 2020 Category: Pharmaceuticals Source Type: news
19.05.20: Berenberg Virtual USA Conference 2020,Tarrytown, U.S.A.
Berenberg Virtual USA Conference 2020,Tarrytown, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 30, 2020 Category: Pharmaceuticals Source Type: news
19.05.20: UBS Virtual Global Healthcare Conference, New York, U.S.A.
UBS Virtual Global Healthcare Conference, New York, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 30, 2020 Category: Pharmaceuticals Source Type: news
28.04.20: CEO Werner Baumann at the Bayer AG Annual Stockholders' Meeting:
"We're active in the right businesses"Coronavirus crisis: Employee safety at the top of the agenda / First DAX company to hold virtual stockholders' meeting / Strategic and operational targets attained in 2019 / Dividend of 2.80 euros per share proposed / Good start to fiscal 2020 / Winkeljohann to succeed Wenning as Supervisory Board Chairmanmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 28, 2020 Category: Pharmaceuticals Source Type: news
27.04.20: First quarter of 2020:
Bayer: Good start to 2020 - activities marked by COVID-19Employee safety and business continuity are top priorities / Wide-ranging humanitarian and social engagement / Group sales increase by 6.0 percent (Fx & portfolio adj.) to 12.845 billion euros / EBITDA before special items up by 10.2 percent to 4.391 billion euros / All divisions report higher sales and earnings - strong demand at Consumer Health / Net income advances by 20.0 percent to 1.489 billion euros / Core earnings per share increase by 9.9 percent to 2.67 euros / Outlook for 2020: impact of COVID-19 not yet reliably quantifiablemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 27, 2020 Category: Pharmaceuticals Source Type: news
21.04.20: Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatmentsInvestigation of combination therapies including Bayer's chloroquine and interferon beta-1b to foster much needed solutions for patients in fight against coronavirus pandemic / Bayer Canada to make CAD 1.5 million (approximately 1 million euros) financial commitment and to supply products in support of the research / Plans to include more than 60 contributing research locations involving 6.000 patientsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - April 21, 2020 Category: Pharmaceuticals Source Type: news
